In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Research & Development Innovation Business Strategies

Alchemab Is Bringing A New Meaning To Patient-Centered Care

British-Bostonian Biotech Is Working Backwards To Explain Disease Resilience

  • Analysis

Executive Summary

Alchemab Therapeutics sequences the antibodies of patients who prove especially resilient to hard-to-treat diseases to try and find therapeutic targets.

You may also be interested in...



Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets

Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.

Hyloris Lines Up Hectic Year Of Clinical Trials And Major US Launch

Hyloris has an eventful year ahead as it plans to conduct numerous trials for products in its ever-expanding pipeline and launch Maxigesic IV in the US.

Successful Cortrophin Gel Launch Could Drive Growth At ANI For Years To Come

The launch of ANI Pharmaceutical’s Cortrophin gel has reignited interest in the ACTH drug category, and appears set to drive growth at the company for the foreseeable future.

Table

View full table

Topics

Related Companies

Tags:
Research & Development Innovation Business Strategies
Latest Headlines

Mpox And Newfound ‘Punching Power’ Are Bringing Bavarian Nordic Closer To $1bn Target

Ukraine’s Plea To Industry: Restart Clinical Trials And Give Us New ‘Weapons’ To Fight Cancer

Backed By Big Names, Etherna Hopes To Disrupt mRNA Space

Podcast: OxSonics Hopes To Use Ultrasound To Enhance Drug Efficacy – Without Reformulation

See All
UsernamePublicRestriction

Register

IV146723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By